Does Rallies show Form 4 insider transactions for NXGL?

Yes. Rallies tracks NXGL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NXGL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NXGL. It does not provide personalized investment advice.

NXGL (NexGel, Inc Common Stock) Stock Analysis - Insider Trades

NexGel, Inc Common Stock (NXGL) is a publicly traded Healthcare sector company. As of May 19, 2026, NXGL trades at $0.61 with a market cap of $4.66M and a P/E ratio of -1.35. NXGL moved +9.57% today. Year to date, NXGL is -71.77%; over the trailing twelve months it is -78.80%. Its 52-week range spans $0.48 to $5.10. Analyst consensus is buy with an average price target of $2.00. Rallies surfaces NXGL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NXGL stock inside the company?

Recent NXGL insider activity includes Levy Adam R. sold 4.00K, Levy Adam R. sold 6.00K, Levy Adam R. sold 4.00K, Henry Scott Robert sold 7.17K, and Levy Adam R. sold 2.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NXGL Key Metrics

Key financial metrics for NXGL
Metric	Value
Price	$0.61
Market Cap	$4.66M
P/E Ratio	-1.35
EPS	$-0.38
Dividend Yield	0.00%
52-Week High	$5.10
52-Week Low	$0.48
Volume	388.13K
Avg Volume	0
Revenue (TTM)	$11.42M
Net Income	$-2.89M
Gross Margin	39.48%

Recent NXGL Insider Trades

Levy Adam R. sold 4.00K (~$6.29K) on Dec 24, 2025.
Levy Adam R. sold 6.00K (~$9.66K) on Dec 22, 2025.
Levy Adam R. sold 4.00K (~$10.08K) on Nov 6, 2025.
Henry Scott Robert sold 7.17K (~$18.30K) on Oct 3, 2025.
Levy Adam R. sold 2.40K (~$6.12K) on Oct 3, 2025.

Latest NXGL News

NEXGEL Patch Cuts Laser Plume 95.6%, Lowers Pain Scores by 31% — May 19, 2026
NEXGEL Hires Sales Leader Who Generated $50M Biologics Revenue for BIONX Surgical — May 13, 2026
NEXGEL appoints Ian Blackman as CFO to lead Celularity acquisition integration — Apr 27, 2026
NEXGEL Delays Shareholder Call, Negotiating New Financing for Celularity Deal — Apr 15, 2026
NEXGEL to Pay $15M Upfront for Biomaterials Portfolio, Triples Revenue — Mar 12, 2026

NXGL Analyst Consensus

1 analysts cover NXGL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.00.

Common questions about NXGL

Who is trading NXGL stock inside the company?: Recent NXGL insider activity includes Levy Adam R. sold 4.00K, Levy Adam R. sold 6.00K, Levy Adam R. sold 4.00K, Henry Scott Robert sold 7.17K, and Levy Adam R. sold 2.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NXGL?: Yes. Rallies tracks NXGL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NXGL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NXGL. It does not provide personalized investment advice.